What is the partnership between TAI-SIN PHARMA and Samil Pharmaceutical?

TAI-SIN PHARMA granted Samil exclusive rights to commercialize APP13007 in Vietnam.

What is APP13007 used for?

It is an ophthalmic suspension for treating inflammation and pain after cataract surgery.

Why is Vietnam the target market?

Vietnam performs 300,000 cataract surgeries annually with steady market growth.

What kind of company is Samil Pharmaceutical?

A South Korean pharma firm founded in 1947, specializing in ophthalmology and global expansion.

What are TAI-SIN PHARMA’s next steps after this deal?

It may expand to other ASEAN markets using Vietnam as a strategic entry point.

ASEAN Finance / TAI-SIN PHARMA Signs New Drug Licensing Agreement to Enter Vietnam's Ophthalmic Treatment Market

Published Jun 11, 2026 9:52 PM ・ Updated Jun 14, 2026 12:10 AM ・ 4 min read ・ Source: CNA (Central News Agency)

TAI-SIN PHARMA has signed a licensing agreement with South Korea's Samil Pharmaceutical, granting exclusive commercialization rights for its new ophthalmic drug APP13007 in Vietnam, aiming to capture growing post-surgical eye care demand.

ASEAN Finance Special Report (Total 300 articles)

Stay ahead of the New Southbound Policy and track ASEAN's economic pulse. CNA's 'Southeast Asia Financial Information Network' delivers daily curated financial headlines from Thailand, Vietnam, Indonesia, Malaysia, and the Philippines. Whether it's government policies, industry trends, or investment opportunities, stay informed with real-time insights to seize market advantages.

(CNA, Taipei, June 11) Ophthalmic pharmaceutical company TAI-SIN PHARMA announced today that it has signed a licensing agreement with Samil Pharmaceutical, granting exclusive commercialization rights for its new drug APP13007 (0.05% Clotrimazole Propionate Ophthalmic Suspension) in the Vietnamese market.

TAI-SIN PHARMA stated that Vietnam performs approximately 300,000 cataract surgeries annually, with stable market demand growing at 5% per year. The annual sales of Vietnam's ophthalmic corticosteroid market reach USD 4.26 million. Leveraging Samil Pharmaceutical's expertise in ophthalmic drugs as a core business focus, TAI-SIN PHARMA expects this partnership to significantly boost the sales of its new post-operative inflammation and pain treatment drug APP13007 in Vietnam, bringing positive impacts to the company's financial and business development.

Regarding Samil Pharmaceutical, TAI-SIN PHARMA noted that the company was established in 1947 and headquartered in Seoul, South Korea. It is a pharmaceutical company with specialized knowledge in ophthalmology, hepatobiliary and gastrointestinal medications, and central nervous system drugs. As part of its global expansion strategy, Samil has established overseas subsidiaries in North America, Vietnam, and Japan. 1150611

Stand with the truth. Every sponsorship helps safeguard press freedom.

Download CNA's 'Breaking News' app to stay updated in real time.

Text, images, and videos on this website may not be reproduced, broadcast, or transmitted without authorization.

FACT BOX

Source: CNA (Central News Agency)
Category: Partnership
Organizations: Samil Pharmaceutical

ASEAN Finance / TAI-SIN PHARMA Signs New Drug Licensing Agreement to Enter Vietnam's Ophthalmic Treatment Market

⚡ Key Points

FACT BOX

Editorial & Verification Standards

FAQ

Cite this article — HOW TO CITE

AI CRAWLER ACTIVITY